Elan Corp, plc (ADR) (NYSE:ELN)

Take up of Tysabri is being underestiamted by the popular press, and Elan's pipeline of other programs is underappreciated.

Tysabri will gain momentum as MS community voice grows over its top risk/reward. AD pipeline and Nanotech future are also very bright.

about to have a big run up with new clinical trial

Tysabri for multiple sclerosis and new products for altheizmer diseases will made a winner of this one.This will take time. In two years will double and thats the beginning

Elan's Tysabri is only the tip of this Iceberg and a large chunk of ice it is. If Tysabri reaches full potential an absolutely conservative estimate is $30 a share. In addition to Tysabri are two other aspects to this business;
1- Alzheimers Drug soon to be in phase 3 and possibly fast tracked by the FDA
2- Nano crystal technologies which are slowly ramping up in the background with many joint venture deals being signed.

ALL THREE OF THESE ( EXTREMELY CONSERVATIVE) = $60

Despite intruiging P1 data, the unclear role of anti-amyloid agents in the onset and progression of AD will likely slow the potential for early anti-amyloid monotherapies, including ELN's AAB-001.

Investors underestimate the effectiveness of Tysabri and overestimate its side effects. AAB-001 peek will be in H2 of '06 and, if successful, will be a huge catalyst for the stock.

tysabri and alz sales and Phase 3 data coming through

Projected share price of $33 by 2010

Uptake of Tysabri, Phase III of Alzheimer's drugs...

The benefit of Tysabri to those afflicted with ms will become obvious, and other drugs in the pipeline will emerge.

Tysabri sales, AD development and profitabilty in 6 month timeframe

Tysabri sales will soar.

ms drug is great. i can't remember the other drugs their coming out with, but i hope soon

The sales results of MS drug Tysabri could be beyond the expectation.

Tysbari will be a real winner. Good pipeline.

tysobria is back on the market with huge pot-
ential

M.S. drug that really does help.

This is a biotech company with a drug for multiple sclerosis which caused a few deaths a year or two ago. Horrible as that sounds, the drug cut down on MS lesions in the brains of test subjects by 96%, something unehard of with other drugs. While it may not be a first line drug at this point, it may well be better than other even more toxic drugs used to treat severe MS cases. It is now back for use in the more severe cases, and I think will be used more and more in the future. The complications came about mainly when it was used with other MS drugs, something which will obviously not be done now.

Also, the company has tested the first Alzheimer's vaccine. Preliminary studies is that it stops (yes, stops) the abnormal areas called neurofibrillary tangles, in the brains of Alzheimer's sufferers. While still some time off marketing, the vaccine would be nothing less than a phenomenal medical and financial coup for the company. In the short term (six to twelve months), I see the MS drug (Tysabri) doing better and better (the stock was at around sixty when the drug first came out and dropped to three when the trouble came about) over the next six to twelve months. When and if the Alzheimer's vaccine comes out, I believe the result to the company's value will be phenomenal.